The platform Verafeye Luma Vision's Blickfeld uses a proprietary catheter sensor combined with advanced imaging to deliver high-resolution 360-degree images of the beating heart and surrounding anatomy. This provides physicians with access to accurate cardiac data with seamless image integration and an unprecedented Blickfeld. The platform is compatible with other catheters and systems. The German-Irish company Startup based in Dublin and Munich, promises treatment with improved prospects of success and a simplified operation.
Fionn Lahart, CEO of Luma Vision, explains:
"Physicians need accurate, real-time data directly in the catheterization lab to treat their patients. Our goal with Verafeye is to provide physicians with the exact imaging data they need to successfully treat as many patients as possible with various cardiac arrhythmias and structural heart disease. We believe Verafeye can be the foundation of interventional medical imaging for years to come. By developing a technology platform tailored to specific cardiology therapies, we enable physicians to deliver precise treatments for the benefit of patients and the healthcare system."
Luma Vision developed in Munich
The startup, founded in 2017 by CTO Christoph Hennersperger and CEO Fionn Lahart, has now successfully completed another round of financing. Investors provided a total of €20 million ($22 million). The round is led by existing investors EQT Lifesciences, Atlantic Bridge University Fund, and Imec xpand. Atlantic Bridge Growth, Bayern Kapital, and an unnamed international medical technology company also joined the round. The company plans to invest the new capital in further developing the platform for additional clinical applications in cardiology. FDA approval is also a priority.
“We are delighted to be working with a company like Luma Vision, which is setting new standards in the interventional treatment of a widespread heart disease,”
says Monika Steger, Managing Director of Bayern Kapital. And further:
"Managed from the development office in Munich and the headquarters in Dublin, Luma Vision has the potential to bring about global progress in the treatment of heart diseases associated with an increasingly aging population."
